Published in World J Gastroenterol on January 28, 2014
Clinical application of genetics in management of colorectal cancer. Intest Res (2014) 1.11
Early detection of colorectal cancer: from conventional methods to novel biomarkers. J Cancer Res Clin Oncol (2015) 0.92
CSBF/C10orf99, a novel potential cytokine, inhibits colon cancer cell growth through inducing G1 arrest. Sci Rep (2014) 0.84
Viral oncolysis - can insights from measles be transferred to canine distemper virus? Viruses (2014) 0.82
Fecal DNA testing for colorectal cancer screening: Molecular targets and perspectives. World J Gastrointest Oncol (2015) 0.82
High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Fam Cancer (2016) 0.81
Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med (2016) 0.80
New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol (2016) 0.79
Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy. World J Gastroenterol (2016) 0.77
AKT and JNK Signaling Pathways Increase the Metastatic Potential of Colorectal Cancer Cells by Altering Transgelin Expression. Dig Dis Sci (2015) 0.77
Tumour-associated macrophages correlate with microvascular bed extension in colorectal cancer patients. J Cell Mol Med (2016) 0.77
The Role of Chromosomal Instability and Epigenetics in Colorectal Cancers Lacking β-Catenin/TCF Regulated Transcription. Gastroenterol Res Pract (2016) 0.77
Familial colorectal cancer screening: When and what to do? World J Gastroenterol (2015) 0.77
Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer. BMC Cancer (2016) 0.76
Case-control study of candidate gene methylation and adenomatous polyp formation. Int J Colorectal Dis (2016) 0.75
Colorectal cancer and the KIR genes in the human genome: A meta-analysis. Genom Data (2016) 0.75
Pan-cancer analysis of frequent DNA co-methylation patterns reveals consistent epigenetic landscape changes in multiple cancers. BMC Genomics (2017) 0.75
Association of APC I1307K and E1317Q polymorphisms with colorectal cancer among Egyptian subjects. Fam Cancer (2016) 0.75
Clinicopathologic Significance of Extranodal Tumor Extension in Colorectal Adenocarcinoma with Regional Lymph Node Metastasis. Gastroenterol Res Pract (2016) 0.75
Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. Int J Environ Res Public Health (2016) 0.75
Association of Wilms' tumor 1 gene single-nucleotide polymorphism rs16754 with colorectal cancer. Mol Clin Oncol (2015) 0.75
Epigenetic Biomarkers for the Early Detection of Gastrointestinal Cancer. Gastrointest Tumors (2015) 0.75
Tumour biomarkers: homeostasis as a novel prognostic indicator. Open Biol (2016) 0.75
Impact of Microsatellite Instability in Signet-Ring Cell and Mucinous Components in Patients With Colorectal Carcinoma. Ann Coloproctol (2016) 0.75
The Genome Conformation As an Integrator of Multi-Omic Data: The Example of Damage Spreading in Cancer. Front Genet (2016) 0.75
The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka. BMC Res Notes (2017) 0.75
Association of monoallelic MUTYH mutation among Egyptian patients with colorectal cancer. Fam Cancer (2017) 0.75
The role of pparγ and autophagy in ros production, lipid droplets biogenesis and its involvement with colorectal cancer cells modulation. Cancer Cell Int (2017) 0.75
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15
Cancer epigenetics: from mechanism to therapy. Cell (2012) 7.74
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol (2007) 5.68
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol (2010) 5.62
Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology (2008) 5.19
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol (2011) 4.95
Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (2011) 4.84
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol (2005) 3.48
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res (2006) 3.17
Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol (2011) 3.15
Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res (2005) 2.92
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol (2012) 2.86
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer (2011) 2.68
Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut (2008) 2.68
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem (2009) 2.57
Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res (2012) 2.50
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst (2012) 2.49
Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One (2008) 2.46
Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun (1983) 2.41
Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA (2013) 2.26
Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res (2011) 2.06
SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res (2005) 2.05
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol (2012) 1.97
TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med (2012) 1.94
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer (2010) 1.83
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol (2002) 1.74
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol (2011) 1.61
Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60
Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther (2005) 1.57
Distinct genetic alterations in colorectal cancer. PLoS One (2010) 1.56
Aberrant methylation of genes in stool samples as diagnostic biomarkers for colorectal cancer or adenomas: a meta-analysis. Int J Clin Pract (2011) 1.54
Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol (2011) 1.50
Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology (2009) 1.49
Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology (2008) 1.43
Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One (2010) 1.40
A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol (2008) 1.40
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res (2012) 1.39
Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut (2013) 1.37
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer (2013) 1.32
Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem (2012) 1.26
A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One (2012) 1.24
SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer (2008) 1.23
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer (2009) 1.22
Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol (2012) 1.19
Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS One (2012) 1.14
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer (2012) 1.13
PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One (2013) 1.13
Epigenetic biomarkers of colorectal cancer: Focus on DNA methylation. Cancer Lett (2011) 1.05
Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level. Ann Surg Oncol (2012) 1.04
Epigenetic drivers of genetic alterations. Adv Genet (2010) 1.02
Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology (2010) 1.01
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat (2011) 0.98
The molecular biology of colorectal carcinoma and its implications: a review. Surgeon (2011) 0.98
First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol (2009) 0.97
Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep (2013) 0.96
APC polymorphisms and the risk of colorectal neoplasia: a HuGE review and meta-analysis. Am J Epidemiol (2013) 0.96
Prognostic and predictive factors in colorectal cancer. Chirurgia (Bucur) (2012) 0.95
Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. J Dig Dis (2013) 0.95
The prognostic significance of APC gene mutation and miR-21 expression in advanced-stage colorectal cancer. Colorectal Dis (2013) 0.95
Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer. Neoplasia (2012) 0.95
Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J Mol Diagn (2013) 0.94
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol (2012) 0.94
Epigenetic alteration: new insights moving from tissue to plasma - the example of PCDH10 promoter methylation in colorectal cancer. Br J Cancer (2013) 0.94
The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis. Br J Cancer (2013) 0.93
Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer. Ann Surg Oncol (2013) 0.93
Genome-wide screening of genes regulated by DNA methylation in colon cancer development. PLoS One (2012) 0.92
Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. Clin Invest Med (2011) 0.92
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res (2013) 0.91
Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer. Cancer Epidemiol Biomarkers Prev (2012) 0.89
Specific genomic aberrations in primary colorectal cancer are associated with liver metastases. BMC Cancer (2010) 0.89
Diagnostic value of stool DNA testing for multiple markers of colorectal cancer and advanced adenoma: a meta-analysis. Can J Gastroenterol (2013) 0.89
Lymphovascular invasion of colorectal cancer is correlated to SPARC expression in the tumor stromal microenvironment. Epigenetics (2011) 0.88
Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients. Med Oncol (2013) 0.88
KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. Med Oncol (2013) 0.88
Clinical applications of DNA methylation biomarkers in colorectal cancer. Epigenomics (2013) 0.88
Clinical significance of microsatellite instability in colorectal cancer. Langenbecks Arch Surg (2013) 0.87
Common genetic variants in Wnt signaling pathway genes as potential prognostic biomarkers for colorectal cancer. PLoS One (2013) 0.86
Chemotherapy of MMR-deficient colorectal cancer. Fam Cancer (2013) 0.85
Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. Clin Colorectal Cancer (2013) 0.85
Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays. Mod Pathol (2012) 0.85
Prognostic Impact of del(17p) and del(22q) as assessed by interphase FISH in sporadic colorectal carcinomas. PLoS One (2012) 0.84
Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients. PLoS One (2013) 0.84